The preclinical imaging market is expected to register a CAGR of nearly 6.00% during the forecast period. This report is segmented by modality and geography.
The major factors leading to the growth of the preclinical imaging market include the technological advancements in molecular imaging, increasing demand for non-invasive small animal imaging techniques, and an increase in preclinical research funding, by both private and public organizations.
Molecular imaging is a rapidly developing multidiscipline, which involves molecular biology, chemistry, computer, engineering, and medicine. It can recognize non - invasive and real-time visualization, measurement of the physiological or pathological process in the living organism at the cellular or molecular level.
Multimodal molecular imaging can play important role in the clinical care of various diseases by improving clinicians’ ability to perform screening, surveillance, staging, prognosis, planning and therapy guidance, monitoring therapy efficacy, and assessing recurrence.
With its rapid technological advances, presymptomatic detection, targeted therapy, and personalized medicine may be possible in the near future through the use of multimodal molecular imaging. Aspect imaging developed Aspect’s M2 platform and the suite of products enable researchers to harness the power and quantitative insights of MRI for small animal phenotyping and drug development but without the cost, complexity, and technical burden of traditional MRI systems.
In 2018, next-generation SPECT cameras with cadmium zinc telluride (CZT) detectors can lower patient radiation dose and shorten examination time. Thus, the introduction of innovative products is likely to augment the growth of the preclinical imaging market.
Key Market Trends
Micro-Ultrasound is the Segment by Modality and is Expected to be the Fastest Growing Market
Micro-ultrasound is a miniature version of ultrasound that has a wider range of applications, especially in research related to the small animal models. These smaller versions of imaging techniques boost the efficacy of the techniques. Additionally, they reduce the number of animals required for a particular study. Over the past decade, preclinical imaging has emerged as an important tool to facilitate biomedical discovery. The high-frequency micro-ultrasound steadily evolved in the post-genomic era as a rapid, comparatively inexpensive imaging tool for studying normal development, and models of human disease in small animals. One of the fundamental barriers to this development was the technological hurdle associated with high-frequency array transducers. The applications of preclinical micro-ultrasound are explored for developmental biology, cancer, and cardiovascular disease. With respect to the future, the latest developments in high-frequency ultrasound imaging are also being developed. The combination of multiple imaging modalities in preclinical studies will help the researchers to understand the molecular, cellular, and physiological changes in living animals and to predict the outcome of new treatments in patients. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.
North America is Expected to Dominate the Preclinical Imaging Market
North America is expected to dominate the preclinical imaging market, due to the fact that the region has the developed infrastructure, a large number of preclinical projects, and higher adoption rates of technically advanced devices in the region.
The United States is also found to be dominating the market, owing to the presence of established infrastructure and the presence of major public and private companies.
The preclinical imaging is increasingly used in target identification, compound optimization, and in the drug development process.
The increased research and development funding that is taking place, coupled with the presence of a highly developed research infrastructure, is accelerating the growth of the preclinical imaging market in the United States.
Also, market players are partnering with distributors to increase their product reach. For instance, in September 2017, Aspect Imaging, one of the market player in design and development of compact magnetic resonance systems for preclinical, medical, and industrial applications, announced that Quantum analytics would be its exclusive US Distributor for Aspect Imaging’s Industrial product portfolio.
Thus, all these factors have contributed in the growth of the market.
The market studied is a moderately consolidated market owing to the various small and large market players. Some of the market players are Aspect Imaging Ltd, Bruker Corporation, Fujifilm Holdings Corporation, Li-Cor Biosciences, Mediso Ltd, Milabs BV, MR Solutions Ltd, PerkinElmer Inc., and Trifoil Imaging.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support